

# DEXCOM INC.

ISIN: US2521311074 WKN: 252131107 Asset Class: Stock

## Company

2021/05/07 22:00:00

**Dexcom**<sup>®</sup>  
CONTINUOUS GLUCOSE MONITORING

Price  
**358.74**  
USD

Difference  0.39%(1.40)



## Contact Details

DEXCOM, INC. Tel: 1-858-200-0200  
-- Fax: --  
6340 Sequence Drive Web: <http://www.dexcom.com>  
92121 San Diego E-mail: --

## Company Profile

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	3,424,800,000		1,969,400,000		1,699,500,000	
<b>Common stock capital</b>		100,000		100,000		100,000
<b>Fixed assets</b>	957,900,000		425,600,000		216,500,000	
<b>Equity capital of a company</b>		1,826,500,000		882,600,000		663,300,000
<b>Cash and cash equivalents</b>	817,600,000		446,200,000		1,137,000,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		614,100,000		360,200,000		222,400,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		1,942,100,000		1,152,200,000		1,030,300,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		26,900,000		5,700,000		12,700,000
<b>Total assets</b>	4,382,700,000	4,382,700,000	2,395,000,000	2,395,000,000	1,916,000,000	1,916,000,000

## Balance notes

	2020	2019	2018
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	6,400	5,200	2,800
<b>Equity ratio</b>	41.68%	36.85%	34.62%
<b>Debt-equity ratio</b>	139.95%	171.36%	188.86%

## Others

	2020	2019	2018
<b>Tax Expense Rate</b>	-119.38%	2.98%	-0.47%

**DEXCOM INC.**

ISIN: US2521311074

WKN: 252131107

Asset Class: Stock

**Income statement**

	2020	2019	2018
<b>Turnover</b>	1,926,700,000	1,476,000,000	1,031,600,000
<b>Net income</b>	493,600,000	101,100,000	-127,100,000
<b>EBIT</b>	245,739,200	112,799,680	-87,687,040
<b>Operating income before taxes</b>	225,000,000	104,200,000	-126,500,000
<b>Cash Flow</b>	475,600,000	314,500,000	123,200,000
<b>Net interest income</b>	-71,500,000	-31,900,000	-20,700,000
<b>Research and development expenses</b>	359,900,000	273,500,000	412,000,000
<b>Income taxes</b>	-268,600,000	3,100,000	600,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	249,508	235,252	305,354

**Board of Directors****Members of Management Board**

Barbara Kahn	Member of Board of Directors
Eric Topol	Member of Board of Directors
Jay Skyler	Member of Board of Directors
Bridgette Heller	Member of Board of Directors
Karen Dahut	Member of Board of Directors
Kyle Malady	Member of Board of Directors
Mark Foletta	Member of Board of Directors
Nicholas Augustinos	Member of Board of Directors
Richard Collins	Member of Board of Directors
Steven Altman	Member of Board of Directors
Kevin Sayer	Chairman of Managing Board
Andrew Balo	Member of Executive Committee
Barry Regan	Member of Executive Committee
Donald Abbey	Member of Executive Committee
Jacob Leach	Member of Executive Committee
Jereme Sylvain	Member of Executive Committee
Patrick Murphy	Member of Executive Committee
Quentin Blackford	Member of Executive Committee
Sadie Stern	Member of Executive Committee
Sean Christensen	Member of Executive Committee